Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moolec ScienceMLEC +0.83%44 3-Year EBITDA Growth Rate is -141.40% as of Dec. 2025. GuruFocus rates MLEC with a GF Score™ of 44/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,135 Biotechnology companies, Moolec Science ranks worse than 98.94% on this metric.
During the past 12 months, Moolec Science's average EBITDA Per Share Growth Rate was -1935.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -141.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Moolec Science was -141.40% per year. The lowest was -141.40% per year. And the median was -141.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Moolec Science 3-Year EBITDA Growth Rate Related Terms
MLEC vs CELZ, DRMA, ENVB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Moolec Science's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Moolec Science's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -141.40% mean?
Moolec Science (MLEC) has a 3-Year EBITDA Growth Rate of -141.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #1123 out of 1135 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Moolec Science's 3-Year EBITDA Growth Rate too high?
Moolec Science's current 3-Year EBITDA Growth Rate is -141.40%. Based on the distribution chart, Moolec Science ranks #1123 out of 1135 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's 3-Year EBITDA Growth Rate compare to CELZ and DRMA?
According to the Biotechnology industry distribution chart, Moolec Science ranks #1123 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Moolec Science in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Moolec Science and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current 3-Year EBITDA Growth Rate is -141.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.33 — trading 91.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -141.40%. Moolec Science's overall GF Score™ is 44/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Moolec Science (MLEC), the current 3-Year EBITDA Growth Rate is -141.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.33 is trading 91.4% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
3-Year EBITDA Growth Rate: -141.40%
GF Value™: $84.84 vs. price of $7.33 (91.4% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
44GF Score
Get the complete analysis for MLEC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
